Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A Network Meta-Analysis. J of Skin 2024, 8 (1), s313. https://doi.org/10.25251/skin.8.supp.313.